人工智能与放射科医生在标准CT上检测胰腺癌(PANORAMA):国际配对非劣效性确证性观察研究
PANORAMA国际配对非劣效性研究以3440例患者建立开源基准,评估AI在常规CT上检测胰腺导管腺癌(PDAC)的性能。AI有望更早发现胰腺癌。
要点
- 研究基于国际多中心数据建立开源基准,支持AI辅助早期检测的潜在价值。
核心结论
- AI在常规CT上检测PDAC的平均性能优于放射科医生,显示出更早发现癌症并改善患者结局的潜力。
研究设计与样本
- 国际配对非劣效性确证性观察研究,训练与调优队列2310例来自荷兰和美国4家三级中心,隔离测试队列1130例来自荷兰、瑞典和挪威5家三级中心。
- 在测试队列391例子集上开展多读者多病例观察研究,纳入68名放射科医生(40中心、12国家,中位经验9·0年,IQR 6·0-14·5)。
- 参考标准由组织病理学和至少3年临床随访确立,主要终点为AI对比放射科医生检测PDAC的AUROC均值,预设非劣效界值0·05。
主要发现
- 3440例纳入患者中1103例(32%)为阳性PDAC诊断,中位年龄67岁(IQR 58-74),女性1511例(44%)。
- 隔离测试队列1130例(406例组织学确诊PDAC)中AI的AUROC为0·92(95%CI 0·90-0·93)。
- 读者研究子集391例(144例组织学确诊PDAC)中AI的AUROC为0·92(95%CI 0·89-0·94),放射科医生汇总AUROC为0·88(95%CI 0·85-0·91),非劣效p<0·0001、优效p=0·001。
关键数值与推荐
- AI对比放射科医生检测PDAC的AUROC差异预设非劣效界值为0·05。
- AI在隔离测试队列的AUROC为0·92(95%CI 0·90-0·93)。
- AI在读者研究子集的AUROC为0·92(95%CI 0·89-0·94),放射科医生为0·88(95%CI 0·85-0·91)。
临床怎么用
- AI可作为常规CT上PDAC检测的辅助工具,其平均诊断性能不劣于且优于放射科医生,可能帮助更早发现胰腺癌。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has the worst prognosis among major cancer types, primarily due to late diagnosis on contrast-enhanced CT. Artificial intelligence (AI) can improve diagnostic performance, but robust benchmarks and reliable comparison to radiologists' performance are scarce. We established an open-source benchmark with the aim of investigating AI systems for PDAC detection on CT and compared them to radiologists' performance, at scale. METHODS: In this international, paired, non-inferiority, confirmatory, observational study (PANORAMA), the AI system was trained and externally validated within an international benchmark, with a cohort of 2310 patients from four tertiary care centres in the Netherlands and the USA for training (n=2224) and tuning (n=86), and a sequestered cohort of 1130 patients from five tertiary care centres (the Netherlands, Sweden, and Norway) for testing. A multi-reader, multi-case observer study with 68 radiologists (40 centres, 12 countries; median 9·0 [IQR 6·0-14·5] years of experience) was conducted on a subset of 391 patients from the testing cohort. The reference standard was established with histopathology and at least 3 years of clinical follow-up. The primary endpoint was the mean area under the receiver operating characteristic curve (AUROC) of the AI system compared to that of radiologists at PDAC detection on CT. The study protocol and statistical plan were prespecified to test non-inferiority (considering a margin of 0·05), followed by superiority towards the AI system. This study is registered with Zenodo (https://doi.org/10.5281/zenodo.10599559) and is complete. FINDINGS: Of the 3440 (1511 [44%] female, 1929 [56%] male; median age 67 [IQR 58-74] years) included patients (Jan 1, 2004 to Dec 31, 2023), 1103 (32%) received a positive PDAC diagnosis. In the sequestered testing cohort of 1130 patients (406 with histologically confirmed PDAC), AI achieved an AUROC of 0·92 (95% CI 0·90-0·93). In the subset of 391 patients (144 [37%] with histologically confirmed PDAC) used for the reader study, AI achieved statistically non-inferior (p<0·0001) and superior (p=0·001) performance with an AUROC of 0·92 (95% CI 0·89-0·94), compared to the pool of 68 participating radiologists, with an AUROC of 0·88 (0·85-0·91). INTERPRETATION: AI demonstrated substantially improved PDAC detection on routine CT scans compared to radiologists on average, showing potential to detect cancer earlier and improve patient outcomes. FUNDING: European Union's Horizon 2020 research and innovation programme.
引用
- Alves N, Schuurmans M, Rutkowski D, et al. Artificial intelligence and radiologists in pancreatic cancer detection using standard of care CT scans (PANORAMA): an international, paired, non-inferiority, confirmatory, observational study. Lancet Oncol. 2025. PMID: 41275871. doi:10.1016/S1470-2045(25)00567-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。